Developing a targeted gene editing tool for mosquitoes that spread diseases.
A Cell-specific modified CRISPR/Cas9 system for conditional gene disruption in Aedes aegypti
This study is working on a special tool to change the genes of yellow fever mosquitoes, which spread diseases like dengue and chikungunya, to help scientists learn more about them and find better ways to control their populations and reduce the spread of these illnesses.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brandeis University NIH-funded |
| Lab location | 1 site (Waltham, United States) |
| Project ID | NIH-10739805 on NIH RePORTER |
What this research studies
This research focuses on creating a modified CRISPR/Cas9 system specifically designed for the yellow fever mosquito, Aedes aegypti, which is known to transmit diseases like dengue and chikungunya. By enhancing the precision of gene disruption in these mosquitoes, the project aims to better understand their biology and behavior, which could lead to more effective control strategies against mosquito-borne diseases. The approach involves developing a toolkit that allows researchers to target specific cells within the mosquito, making it easier to study the effects of gene disruption. This could ultimately inform new methods for controlling mosquito populations and reducing disease transmission.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals living in regions affected by mosquito-borne diseases such as dengue and chikungunya.
Not a fit: Patients who do not live in areas where Aedes aegypti is prevalent may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved strategies for controlling mosquito populations and reducing the incidence of diseases they transmit.
How similar studies have performed: Other research has shown success with CRISPR/Cas9 technology in various organisms, indicating potential for this novel approach in mosquitoes.
Where this research is happening
Waltham, United States
- Brandeis University — Waltham, United States (Active)
Researchers
- Principal investigator: Garrity, Paul — Brandeis University
- Study coordinator: Garrity, Paul
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.